Lancet oncol: Phase 3 daratumumab + lenalidomide first-line treatment of multiple myeloma not suitable for transplantation can be expected!

In the main analysis of the Phase 3 MAIA trial (median follow-up of 28.

This article reports the latest efficacy and safety results of the interim analysis of the overall survival scheduled for the trial

The MAIA study is an ongoing, multi-center, randomized, open-label phase 3 trial that recruits 18-year-old, newly diagnosed, age-dependent (>65 years old) or combined from 176 hospitals in 14 countries Patients with multiple myeloma who cannot undergo high-dose chemotherapy + autologous stem cell transplantation

Progression-free survival in both groups

From March 18, 2015 to January 15, 2017, a total of 952 patients underwent condition assessment, of which 737 were recruited and randomly assigned to the daratumumab group (n=368) or the control group ( n=369)

Overall survival of the two groups

The most common (>15%) treatment-related adverse events of grade 3 and above were neutropenia (daratumomab vs control group: 54% vs 37%), pneumonia (19% vs 11%) , Anemia (17% vs 22%) and lymphopenia (16% vs 11%)

In conclusion, daretrolumab combined with lenalidomide and dexamethasone can prolong the overall survival and overall survival of newly diagnosed multiple myeloma patients who are not suitable for stem cell transplantation compared with nalalidomide and dexamethasone alone.

Thierry Facon, et al.